AIM
BIO icon

Aquila Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Aquila Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,652
Closed -$2.76M – 92
2021
Q4 		$2.76M Buy
+3,652
New +$2.73M 1.33% 25

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aquila Investment Management's BIO Position: Q1 2022 in Review

Aquila Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 3,652 shares — an estimated $2.76M sold.

Aquila Investment Management first reported a position in BIO in Q4 2021 and held it in 1 quarter. The position peaked at $2.76M in Q4 2021. 516 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

  • Aquila Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
  • Aquila Investment Management sold 3,652 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $2.76M.
  • Aquila Investment Management first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and held it in 1 quarter.
  • Aquila Investment Management's Bio-Rad Laboratories Class A position peaked at $2.76M in Q4 2021.
  • 516 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Aquila Investment Management's 13F filing for Q1 2022, filed 4 May 2022.